Press Releases

PONTE VEDRA, Fla., July 24, 2023 — Cadrenal Therapeutics, Inc., (“Cadrenal” or the “Company”) (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the appointment of Robert Lisicki to its Board of Directors and Compensation and Nomination/Governance Committees. Lisicki brings over 25 years of experience in the pharma/biotech sector, including as the Chief Commercial Officer of Arena Pharmaceuticals, where he provided

PONTE VEDRA, Fla., July 14, 2023 — Cadrenal Therapeutics, Inc., (“Cadrenal” or the “Company”) (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced that it has closed its previously announced private placement with an institutional investor for the issuance and sale of 4,285,715 of its shares of common stock at a purchase price of $1.75 per share (or pre-funded warrant in

PONTE VEDRA, Fla., July 12, 2023 — Cadrenal Therapeutics, Inc., (“Cadrenal” or the “Company”) (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced that it has entered into a securities purchase agreement with certain institutional investors for the issuance and sale of 4,285,715 of its shares of common stock at a purchase price of $1.75 per share (or pre-funded warrant in

PONTE VEDRA, Fla., June 1, 2023 — Cadrenal Therapeutics, Inc., (Cadrenal or the Company) (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, announced today that the company will participate in investor and partnering meetings at the BIO International Convention being held June 5-8, 2023 in Boston. During the convention, members of the Cadrenal management team will conduct one-on-one meetings with registered investors

PONTE VEDRA, Fla., May 10, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a corporate update in connection with today’s filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023. Recent Highlights In January 2023, U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for tecarfarin for the prevention